Please assess the completion status of the following clinical trial:

Trial Title: Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Hodgkin's or Hodgkin's lymphoma that has relapsed following either a course of high dose chemotherapy or autologous stem cell transplantation.~* \>= 90 days from prior transplant.~* Have a suitable human leukocyte antigen (HLA)-matched related bone marrow donor or a compatible matched unrelated bone marrow donor by molecular typing at HLA A, B, C, D, DR.~* Physically and psychologically capable of undergoing bone marrow transplantation and its attendant period of strict isolation.~* Age \>= 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Be able to receive 400 cGy Total Body Irradiation (TBI).~* Pulmonary function tests: Diffusing capacity or Transfer factor of the lung for carbon monoxide (DLCO) \>= 50% predicted, the forced expiratory volume in 1 second (FEV1) \>= 50% predicted.~* Left ventricular ejection fraction (LVEF) at least 45% by Multi Gated Acquisition Scan (MUGA) or echocardiogram.~* Renal function: creatinine clearance \> 50 ml/min.~* Liver function tests: \< 3 x Upper Limit of Normal (ULN). Liver function test include serum glutamic oxaloacetic transaminase (SGOT) (Aspartate transaminase (AST)), Serum Glutamic Pyruvate Transaminase (SGPT) (Alanine transaminase (ALT)), and bilirubin.~Exclusion Criteria:~* Human immunodeficiency virus positive (HIV+) patients (test positive for P21 antibodies to HIV).~* Evidence of active infection (have received parenteral antibiotics \<= 2 weeks prior to registration).~* Pregnant or breast-feeding women.~* Curable with any other therapeutic interventions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transplant (Type: EXPERIMENTAL): Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).

Based on this trial design, predict the completion outcome and termination type (if applicable).